drugset / Trial / NCT01779830

A Study of LY2624803 in Participants With Transient Insomnia

NCT01779830

Phase 1 Completed 32 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blind

Summary

The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy people. The study has four treatment periods. Participants will receive a single dose of LY2624803, another sleeping pill, or placebo in each treatment period. The study will last approximately 1 month for each participant.

Timeline

Start
2008-05
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2624803 Small molecule 0.3 mg Oral
Subject LY2624803 Small molecule 3 mg Oral
Subject LY2624803 Small molecule 6 mg Oral
Comparator Zolpidem Small molecule 10 mg Oral

Indications